Mainz Biomed announces registration of ColoAlert in the U.K.

Mainz Biomed (MYNZ) announces that ColoAlert has received official registration with the Medicines and Healthcare products Regulatory Agency, MHRA, and is now authorized for marketing in the United Kingdom. This milestone follows the technology partnership announced earlier this year with EDX Medical Group plc, a leading UK laboratory, and represents an important step toward making Mainz Biomed’s DNA-based colorectal cancer, CRC, screening test, ColoAlert, broadly accessible to patients across the country.